What is Parallel Bio?
Based in Cambridge, Massachusetts, Parallel Bio is at the forefront of the intersection between artificial intelligence and synthetic biology. The company specializes in creating true-to-life models of human biology by integrating advanced organoid technology with predictive AI algorithms. By developing the first platform capable of replicating the human immune system across diverse populations, Parallel Bio provides pharmaceutical partners with a Clinical Trial in a Dish. This innovative approach allows for the rapid identification of disease targets and the assessment of immunotherapy efficacy, effectively mitigating the risks and limitations associated with traditional animal-based testing models.
How much funding has Parallel Bio raised?
Parallel Bio has raised a total of $25.3M across 2 funding rounds:
Angel/Seed
$4.3M
Series A
$21M
Angel/Seed (2022): $4.3M with participation from Refactor Capital, Y Combinator, and Breakout Ventures
Series A (2025): $21M led by Atypical Ventures, Metaplanet, Undeterred Capital, Amplo, and AIX Ventures
Key Investors in Parallel Bio
Metaplanet
Metaplanet is an early-stage investment firm that focuses on backing mission-driven founders working on positively disruptive deep technologies, prioritizing long-term societal impact.
Undeterred Capital
Undeterred Capital partners with founders to commercialize scientific and technological breakthroughs, with a specific focus on AI for drug discovery and synthetic biology.
Breakout Ventures
Breakout Ventures is a venture capital firm focused on investing in transformative companies that leverage scientific innovation and technology to create new markets.
What's next for Parallel Bio?
The recent capital infusion is expected to accelerate the commercialization of Parallel Bio's platform as it deepens its partnerships with Fortune 500 pharmaceutical entities. As the company transitions from its foundational development phase into a period of rapid scaling, the focus will likely shift toward expanding its immune organoid library and enhancing the predictive accuracy of its AI models. By providing a more reliable, human-centric alternative to legacy drug discovery methods, Parallel Bio is well-positioned to capture significant market share in the high-growth immunotherapeutics sector, ultimately shortening the timeline for bringing life-saving treatments to market.
See full Parallel Bio company page
